These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 11110645

  • 21. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G, Greenbaum E, Zakay-Rones Z.
    Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
    Chi RC, Rock MT, Neuzil KM.
    Clin Infect Dis; 2010 May 15; 50(10):1331-8. PubMed ID: 20377407
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ, Gussekloo J, Remmerswaal JE, Remarque EJ, Kroes AC.
    J Med Virol; 2009 May 15; 81(5):908-14. PubMed ID: 19319953
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L.
    Vaccine; 2006 Jan 16; 24(3):254-62. PubMed ID: 16129526
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
    Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P.
    Vaccine; 2009 Dec 09; 27(52):7304-12. PubMed ID: 19849996
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.
    Edwards KM, Dupont WD, Westrich MK, Plummer WD, Palmer PS, Wright PF.
    J Infect Dis; 1994 Jan 09; 169(1):68-76. PubMed ID: 8277200
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS, Chan KH, Tu W, Lau YL, Peiris JS.
    Vaccine; 2009 Jul 30; 27(35):4834-9. PubMed ID: 19523908
    [Abstract] [Full Text] [Related]

  • 37. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 30; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 38. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 39. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2009 Dec 11; 58(48):1351-6. PubMed ID: 20010511
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.